ACEBUTOLOL-100 TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
11-07-2019
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE)
Fáanlegur frá:
PRO DOC LIMITEE
ATC númer:
C07AB04
INN (Alþjóðlegt nafn):
ACEBUTOLOL
Skammtar:
100MG
Lyfjaform:
TABLET
Samsetning:
ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 100MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100/500 COMPRIMES
Gerð lyfseðils:
Prescription
Lækningarsvæði:
BETA-ADRENERGIC BLOCKING AGENTS
Vörulýsing:
Active ingredient group (AIG) number: 0131282001; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2022-07-14
Vara einkenni
Page 1 of 33
PRODUCT MONOGRAPH
Pr
ACEBUTOLOL – 100
Pr
ACEBUTOLOL – 200
Pr
ACEBUTOLOL – 400
Acebutolol Tablets (as Acebutolol Hydrochloride)
Manufacturer Standard
100 mg, 200 mg and 400 mg Tablets
Antihypertensive and Anti-anginal Agent
PRO DOC LTÉE
DATE OF REVISION:
2925, boul. Industriel
July 11, 2019
Laval, Quebec
H7L 3W9
Control Number#:228198
Page 2 of 33
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................................
9
DRUG INTERACTIONS
.............................................................................................................................................
12
DOSAGE AND ADMINISTRATION
.........................................................................................................................
15
OVERDOSAGE
...........................................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................................
17
STORAGE AND STABILITY
......................................................................................................
Lestu allt skjalið
